These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 31098635)

  • 1. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.
    Kang EH; Choi HK; Shin A; Lee YJ; Lee EB; Song YW; Kim SC
    Rheumatology (Oxford); 2019 Dec; 58(12):2122-2129. PubMed ID: 31098635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
    Zhang M; Solomon DH; Desai RJ; Kang EH; Liu J; Neogi T; Kim SC
    Circulation; 2018 Sep; 138(11):1116-1126. PubMed ID: 29899013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
    Su CY; Shen LJ; Hsieh SC; Lin LY; Lin FJ
    Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
    Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
    J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat.
    Shin A; Choi SR; Han M; Ha YJ; Lee YJ; Lee EB; Kang EH
    Semin Arthritis Rheum; 2022 Oct; 56():152080. PubMed ID: 35973263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout.
    Kim SC; Neogi T; Kang EH; Liu J; Desai RJ; Zhang M; Solomon DH
    J Am Coll Cardiol; 2018 Mar; 71(9):994-1004. PubMed ID: 29496000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
    Weisshaar S; Litschauer B; Reichardt B; Gruber F; Leitner S; Sibinovic S; Kossmeier M; Wolzt M
    Rheumatol Int; 2022 Sep; 42(9):1597-1603. PubMed ID: 35589988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout.
    Kang EH; Park EH; Shin A; Song JS; Kim SC
    Eur Heart J; 2021 Nov; 42(44):4578-4588. PubMed ID: 34508567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
    White WB; Saag KG; Becker MA; Borer JS; Gorelick PB; Whelton A; Hunt B; Castillo M; Gunawardhana L;
    N Engl J Med; 2018 Mar; 378(13):1200-1210. PubMed ID: 29527974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA; Akhras KS; Shiozawa A
    Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
    MacDonald TM; Ford I; Nuki G; Mackenzie IS; De Caterina R; Findlay E; Hallas J; Hawkey CJ; Ralston S; Walters M; Webster J; McMurray J; Perez Ruiz F; Jennings CG;
    BMJ Open; 2014 Jul; 4(7):e005354. PubMed ID: 25011991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
    Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
    Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
    Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
    Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. `Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea.
    Jeong H; Choi E; Suh A; Yoo M; Kim B
    Rheumatol Int; 2023 Feb; 43(2):265-281. PubMed ID: 36346443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
    White WB; Chohan S; Dabholkar A; Hunt B; Jackson R
    Am Heart J; 2012 Jul; 164(1):14-20. PubMed ID: 22795277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol.
    Pawar A; Desai RJ; Liu J; Kim E; Kim SC
    J Am Heart Assoc; 2021 Apr; 10(7):e020045. PubMed ID: 33764153
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study.
    Kang EH; Shin A; Park CS; Lee EB; Lee YJ; Curhan G; Choi HK
    Rheumatology (Oxford); 2024 Sep; 63(9):2433-2441. PubMed ID: 38733596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data.
    Singh JA; Cleveland JD
    Ann Rheum Dis; 2017 Oct; 76(10):1669-1678. PubMed ID: 28584186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data.
    Singh JA; Cleveland JD
    Eur Heart J; 2019 Sep; 40(36):3046-3054. PubMed ID: 30919894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.